Table 1.
Clinical data of patients with FIGO stage II–IV tumors (n = 107)
| Median age, y (range) | 59 (39–87) | P (progression-free survival) |
| Median observation time of patients alive, mo (range) | 67 (8–153) | |
| FIGO Stage | n (%) | |
| IIC | 8 (7.5) | 0.2095 |
| IIIA | 3 (2.8) | |
| IIIB | 2 (1.9) | |
| IIIC | 69 (64.5) | |
| IV | 25 (23.4) | |
| Histology | ||
| Serous-papillary | 81 (75.7) | 0.0071 |
| Endometrioid | 13 (12.2) | |
| Clear cell | 10 (9.4) | |
| Mucinous | 3 (2.8) | |
| Disease | ||
| Ovarian | 99 | |
| Primary peritoneal | 7 | |
| Primary fallopian tube | 1 | |
| Grading | ||
| G1 + G2 | 26 (24.3) | 0.6096 |
| G3 | 81 (75.7) | |
| Ascites volume | ||
| ≤500 mL | 43 (40.2) | 0.0014 |
| >500 mL | 54 (50.5) | |
| Unknown | 10 (9.3) | |
| Residual tumor | ||
| ≤1 cm | 62 (57.9) | 0.0191 |
| >1 cm | 43 (40.2) | |
| Unknown | 2 (1.9) | |
| Chemotherapy type | ||
| Adjuvant | 107 (100.0) | |
| Chemotherapy | ||
| Taxane/platinum | 101 (94.3) | |
| Cytoxan/platinum | 3 (2.8) | |
| Platinum only | 2 (1.9) | |
| Taxane | 1 (0.9) |